Publications

Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) Journal of Experimental Medicine. May; 210(5):1021-33. 

Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. (2010) Nature Immunology. September; 11(9): 820-826. 

Clin Cancer Res. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer. Liu Y1, Burness ML2, Martin-Trevino R1, Guy J1, Bai S3, Harouaka R1, Brooks MD1, Shang L1, Fox A1, Luther TK1, Davis A1, Baker TL1, Colacino J1, Clouthier SG1, Shao ZM4,5, Wicha MS1, Liu S6. 

Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? (2016) Pharmacology & Therapetucis 160:65-83 

Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. (2016) J Med Chem 59:4511-25 

Ward A, Khanna KK, Wiegmans, AP. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. (2015) Cancer Treatment Reviews 4: 35-45 

Scott DE, Coyne AG, Venkitaraman A, Blundell TL, Abell C, Hyvonene M. Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases (2015) Chem Med Chem. 10: 296-303. 

Mason JM, Logan HL, budke B, Wu M, Pawlowski M, Weichselbaum RR, Kozikowski AP, Bishop DK, Connell PP. The RAD51-Stimulatory Compound RS-1 Can Exploit the RAD51 Overexpression That Exists in Cancer Cells and Tumors. (2014) Cancer Res 74:3546-55. 

Wiegmans AP, Al-Ejej F, Chee N, Yap P-Y, Gorski JJ, Da Silva L, Boldersoon E, Chenevix-Trench G, Anderson R, Simpson PT, Lakhani SR, Khanna KK. Rad51 supports triple negative breast cancer metastasis. (2014) Oncotarget 5: 3261-3272 

Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, Breggia A, Hedlund J, Emery I, Cavallo F, Jasin M, Ruter J, Mills KD. Attenuating homologous recombination stimulate an AID-induced antileukemic effect. (2013) J Exp Med 210:1021-33 

Huhn D, Bolck HA, Sartori AA. Targeting DNA double-strand break signaling and repair: recent advances in cancer therapy. (2013) Eur J Med Sci. Swiss Med Weekly. 143:w13837 

Renodon-Cornière A, Weigel P, Le Breton M, Fleury F. New Potential Therapeutic Approaches by Targeting Rad51-Dependent Homologous Recombination. (2013) New Research Directions in DNA Repair. Edited by Clark Chen. ISBN 978-953-51-1114-6. 

Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL, Welchselbaum RR, Bishop DK, Connell PP. A chemical compound that stimulates the human homologous recombination protein RAD51. (2008) Proc Natl Acad Sci 105:15848-15853 

Nonaka T, Toda Y, Hiai H, Uemura M, Nakamura M, Yamamoto N, Asato R, Hattori Y, Bessho K, Minato N, Kinoshita K. Involvement of activation-induced cytidine deaminase in skin cancer development. (2016) J Clin Invest.126(4):1367-82 

Xochelli A, Sutton LA, Agathangelidis A, Stalika E, Karypidou M, Marantidou F, Lopez AN, Papadopoulos G, Supikova J, Groenen P, Boudjogra M, Sundstrom C, Ponzoni M, Francova HS, Anagnostopoulos A, Pospisilova S, Papadaki T, Tzovaras D, Ghia P, Pott C, Davi F, Campo E, Rosenquist R, Hadzidimitriou A, Belessi C, Stamatopoulos K. Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. (2015) Am J Pathol.185(6):1740-8.

Lossos IS, Fabregas JC, Koru-Sengul T, Miao F, Goodman D, Serafini AN, Hosein PJ, Stefanovic A, Rosenblatt JD, Hoffman JE. Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. (2015) Leuk Lymphoma.56(6):1750-5. 

Nagata N, Akiyama J, Marusawa H, Shimbo T, Liu Y, Igari T, Nakashima R, Watanabe H, Uemura N, Chiba T. Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by Helicobacter pylori and its decrease following eradication (2014) J Gastroenterol. 49(3):427-35 

Okura R, Yoshioka H, Yoshioka M, Hiromasa K, Nishio D, Nakamura M. Expression of AID in malignant melanoma with BRAF(V600E) mutation (2014) Exp Dermatol. 23(5):347-8. 

Gushima M, Hirahashi M, Matsumoto T, Fujita K, Ohuchida K, Oda Y, Yao T, Iida M, Tsuneyoshi M. Expression of activation-induced cytidine deaminase in ulcerative colitis-associated carcinogenesis. (2011) Histopathology 59(3):460-9. 

Shinmura K, Igarashi H, Goto M, Tao H, Yamada H, Matsuura S, Tajima M, Matsuda T, Yamane A, Funai K, Tanahashi M, Niwa H, Ogawa H, Sugimura H. Aberrant expression and mutation-inducing activity of AID in human lung cancer. (2011) Ann Surg Oncol.18(7):2084-92. 

Klemm L, Duy C, Iacobucci I, Kuchen S, von Levetzow G, Feldhahn N, Henke N, Li Z, Hoffmann TK, Kim YM, Hofmann WK, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber MR, Casellas R, Müschen M. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia. (2009) Cancer Cell. 8;16(3):232-45.

Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F, von Levetzow G, Giebel B, Li A, Hofmann WK, Jumaa H, Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. (2007) J Exp Med. 204(5):1157-66.

Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. (2007).Nat Med 13:470-6 

Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, Chaganti RS, Dalla-Favera R. Expression of the AID protein in normal and neoplastic B cells. (2004) 104(10):3318-25.